* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download ABOARD - Clinical Trial Results
Quantium Medical Cardiac Output wikipedia , lookup
Jatene procedure wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Myocardial infarction wikipedia , lookup
Coronary artery disease wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
History of invasive and interventional cardiology wikipedia , lookup
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS G. Montalescot, on behalf of the ABOARD investigators Funded by the Programme Hospitalier de Recherche Clinique (French Ministry of Health) Sponsored by Assistance Publique-Hopitaux de Paris (AP-HP) Led by the A.C.T.I.O.N. group (Academic Research Organization) Coordinating Center: Pitié-Salpêtrière University Hospital Data Management and Statistics: URC Lariboisière University Hospital Additional support from Eli-Lilly G. Montalescot, disclosure: research grant, consulting or speaker fee from BMS, Boston scientific, Cordis, Daiichi Sankyo, Eli Lilly, GSK, SAG, MSD, The Medicines Company, Medtronic, Novartis, Portola, Schering. Preliminary Results Background Randomized trials have demonstrated that an invasive strategy is superior to a conservative strategy in NSTE-ACS The optimal timing of intervention remains a matter of debate A “primary PCI” approach of NSTE-ACS has not been tested yet Preliminary Results Time to catheterization (hrs) FRISC 2 (1999) TRUCS (2000) EARLY 96 48 LATE 408 120 TIMI-18 (2001) VINO (2002) RITA 3 (2002) ELISA (2003) 22 6 48 6 79 1464 1020 50 ISAR-COOL (2003) ICTUS (2005) TIME-ACS (2008) 3 23 14 86 283 50 Immediate Next morning ABOARD (2009) Preliminary Results Study objective To determine whether immediate intervention (“primary PCI strategy”) is superior to delayed intervention (“next day strategy”) in patients with moderate-to-high risk (TIMI score > 3) non-ST segment elevation ACS. Preliminary Results ABOARD study design NSTE-ACS 2 of 3 Criteria: Ischemic symptom, ST-T change, troponin rise with TIMI score > 3 IVRS RANDOMIZATION Immediate cath Next day cath All PCIs on abciximab 1-month Follow-up Preliminary Results Correlation Between Elevat and Long-term M Troponin during hospitalization % mortality at 42 days 8 ACS 7.5% 20 6 15 6.0% « The preferred biomarker for myocardial necrosis is cardiac troponin » 4 3.4 % 3.7% 10 2 1.0 % 0 <0.4 5 1.7 % <1.0 <2.0 <5.0 <9.0 9.0 0 Cardiac Troponin 1 (ng/ML) 1. Antman EM, et al. N Engl J Med. 1996; 335: 1342-1349. 2. Alexander JH et al. Circulation. 1999; Suppl 1:1-629. 2007 Antman EM et al – NEJM 1996 Nienhuis MB et al - CCI 2008 ALL 1.35 (1.13-1.60) PCI Preliminary Results Outcomes Primary − MI: defined as the peak of troponin I during hodpitalization Secondary 1. Death (any), new MI (CK-MB) or urgent revascularization (PCI or CABG) 2. Death, new MI, urgent revascularization or recurrent ischemia 3. Individual parameters Preliminary Results Statistical Analysis Study Power: 352 patients: 80% power to detect an effect size equal to 0.3 Randomization: Central 24 hour IVRS Analysis: Intention to treat; Tests: Mann- Follow-up: 100% Density Whitney test for non-gaussian quantitative parameters, Chi-square or Fisher’s exact probability tests for qualitative parameters . Troponin levels Preliminary Results Top-10 Recruiting Centers 1- G. Montalescot – Pitié, Paris 2- G. Cayla – Nimes 3- S. Elhadad – Lagny 4- H. Lebreton – Rennes 5- F. Leclercq – Montpellier 6- F. Duclos – Argenteuil 7- J.L. Dubois-Randé – Créteil 8- P.G. Steg – Bichat, Paris 9- L. Payot – Montreuil 10- P. Henry – Lariboisière, Paris Preliminary Results Baseline Characteristics Characteristic Age, mean ± sd, y Female sex, % Weight, mean ± sd, kg Current smoking, % Diabetes mellitus, % Previous CABG, % Previous MI, % Previous PCI, % Previous Stroke, % Cardiac Insufficiency, % Immediate Delayed (N=175) (N=177) 65 ± 12 27.4 77 ± 16 32.0 21.7 5.1 16.6 24.6 5.2 4.0 65± 12 29.4 76 ± 15 33.9 32.2 6.8 18.6 30.5 4.5 4.0 Results Preliminary Index ACS event Entry criteria, (%) Ischemic symptom ST-T segment changes Elevated Troponin I Immediate Delayed (N=175) (N=177) 98.2 69.7 75.4 97.7 76.8 72.9 95.4 22.9 95.5 30.5 TIMI score, (%) >3 >5 Preliminary Results In-hospital medications Immediate Delayed (N=175) (N=177) Aspirin, (%) 99.4 100 Clopidogrel, (%) 96.6 98.9 660 ± 268 663 ± 267 111 ± 40 111 ± 39 Abciximab, (%) 65.1 57.4 Unfractionated heparin only, (%) 5.1 3.4 Low Molecular Weight Heparin only, (%) 68.6 67.2 Both UFH and LMWH, (%) 22.9 28.8 Neither UFH nor LMWH, (%) 2.9 0.6 Beta-blocker, (%) 87.4 85.3 Statin, (%) 94.3 95.5 ACE inhibitor or ARB, (%) 84.5 80.2 Loading dose, mean ± sd, mg Maintenance dose, mean ± sd, mg Preliminary Results Time to catheterization (hrs) IMMEDIATE 96 48 22 DELAYED 408 120 79 VINO (2002) RITA 3 (2002) ELISA (2003) 6 48 6 1464 1020 50 ISAR-COOL (2003) ICTUS (2005) TIME-ACS (2008) ABOARD (2009) median (IQR), hr.min 3 23 14 86 283 50 1.10 20.48 FRISC 2 (1999) TRUCS (2000) TIMI-18 (2001) (0.51-2.03) (17.30-24.36) Preliminary Results Interventions IMMEDIATE DELAYED 87.4 81.8 Left main trunk, (%) 4.1 7.3 Left anterior descending artery, (%) 48.6 45.0 Circumflex artery, (%) 24.7 29.1 Right coronary artery, (%) 24.7 25.2 Coronary bypass graft, (%) 2.1 2.0 Percutaneous Coronary Intervention, (%) 80.1 69.5 Stent (at least one), (% of PCI) 94.0 96.2 DES (at least one), (% of PCI) 47.9 55.2 1.2 ± 0.9 1.2 ± 1.0 11.0 11.3 Radial access (%) Culprit artery Number of stents/patient, mean±sd CABG surgery, (%) Preliminary Results Primary EP (peak of troponin I) 0.02 0.04 0.06 0.08 immediate group delayed group Median, IQR 2.1 (0.3-7.1) p = 0.70 1.7 (0.3-7.2) 0.00 Density 0.10 0.12 0.14 Distribution curves of the peaks values of troponin Peakinvalues of troponin I in the 2 groups the immediate and delayed groups 0 20 40 60 80 100 Troponin I (ng/mL) Preliminary Results Composite Ischemic Endpoints at 1 month % 25 20 15 Immediate Delayed P=0.94 P=0.31 10 5 0 Death / MI / UR Death / MI / UR / RI Key secondary EP Preliminary Results Individual Ischemic Endpoints at 1 month % 20 P=0.08 Immediate Delayed 18 16 14 12 10 8 6 4 2 0 P=0.09 P=0.32 P=0.57 P=0.28 ch G R ec Is A B C rg U U rg as ev R rg U PC I c I M D ea th P=0.62 Preliminary Results Safety outcomes at 1 month Immediate Delayed P Major bleeding at 1 month, (%) 4.0 6.8 0.25 Non-CABG related major bleeding, 2.3 5.1 0.26 CABG-related major bleeding 1.7 1.7 1.00 Transfusion > 2 units 3.4 5.6 0.32 Transfusion > 5 units 1.1 1.1 1.00 2.9 4.5 0.41 Non-CABG thrombocytopenia, (%) 2.3 4.0 0.54 Post-CABG thrombocytopenia, (%) 0.6 0.6 1.00 Thrombocytopenia at 1 month, (%) Preliminary Results Sites of Major Bleedings n 1- Gastro-Intestinal 4 2- Puncture-related 4 3- Hemopericardium 2 4- Intracranial 1 5- Epistaxis 1 6- Hematoma (not puncture-related) 1 unknown 7 One patient had 2 bleeding events Preliminary Results Subgroup analysis (primary EP) Median differences and Hodges-Lehmann CI for the primary end point (peak of troponin) Immediate better Delayed better Preliminary Results Hospital stay Immediate 55 Median, IQR, hrs ( 30; 98) Delayed 77 Median, IQR, hrs ( 49; 145) P<0.001 Preliminary Results Conclusions A « primary PCI strategy » in NSTE-ACS (compared with a rapid intervention on the next day): − is feasible, but does not reduce the risk of MI (primary outcome) − is not associated with significant differences in other efficacy or safety outcomes − does not benefit to a particular subgroup of patients − shortens significantly hospital stay Preliminary Results Thank you Preliminary Results